´ëÇÑÁø´ÜÀ¯ÀüÇÐȸ 2024³â Á¦19Â÷ Çмú´ëȸ (2ÀÏÂ÷) : 2024-06-14
±³À°ÀÏÀÚ : 2024-06-14
±³À°Àå¼Ò : ¿¤¸®¿¡³ªÈ£ÅÚ 3F ÀÓÆ丮¾óȦ, 2F ÄÁº¥¼ÇȦ
±³À°ÁÖÁ¦ : ´ëÇÑÁø´ÜÀ¯ÀüÇÐȸ 2024³â Á¦19Â÷ Çмú´ëȸ (2ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇÑÁø´Ü°Ë»çÀÇÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : Áø´ÜÀ¯ÀüÇÐȸ
´ã´çÀÚ : Á¤¹Ì¼±
¿¬¶ôó : 02-772-9004
À̸ÞÀÏ : ksgd.office@gmail.com
±³À°Á¾·ù : Áø´Ü°Ë»çÀÇÇаú
Âü¼®¿¹»óÀÎ : 500¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 10 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 160,000¿ø
ºñ°í »çÀüµî·Ïºñ : Á¤È¸¿ø 8¸¸¿ø(Àü¹®ÀÇ/±³¼ö/±âŸ), Á¤È¸¿ø 6¸¸¿ø(ÀÓ»óº´¸®»ç), Âü°¡È¸¿ø 12¸¸¿ø(Àü¹®ÀÇ/±³¼ö), Àü°øÀÇ ¸éÁ¦, 7¸¸¿ø(ÀÓ»óº´¸®»ç/Çлý), 15¸¸¿ø(»ê¾÷°è), ÇöÀåµî·Ïºñ: Á¤È¸¿ø 9¸¸¿ø(Àü¹®ÀÇ/±³¼ö/±âŸ) Á¤È¸¿ø 7¸¸¿ø(ÀÓ»óº´¸®»ç), Âü°¡È¸¿ø 13¸¸¿ø(Àü¹®ÀÇ/±³¼ö), 8¸¸¿ø(ÀÓ»óº´¸®»ç/Çлý), 16¸¸¿ø(»ê¾÷°è)
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 06¿ù 14ÀÏ ¼¼¼ÇA(¿¤¸®¿¡³ªÈ£ÅÚ 3F ÀÓÆ丮¾óȦ) 09:00~09:30 À¯ÀüÀÚ°Ë»ç °ü·Ã ¹ý·É ¹× Á¦µµ ¹× À¯ÀüÀÚ°Ë»çÀÇ ¸ñÀû¿¡ µû¸¥ À¯ÀüÀÚ°Ë»ç Ç׸ñ ºÐ·ù ÀÌÇØ ¹Ú°æ¼±(°æÈñÀÇ´ë)
±³À°½Ã°£ 06¿ù 14ÀÏ ¼¼¼ÇA(¿¤¸®¿¡³ªÈ£ÅÚ 3F ÀÓÆ丮¾óȦ) 09:30~10:00 ÅÂ¾Æ ¹× ¹è¾Æ ´ë»ó À¯ÀüÀÚ °Ë»çÀÇ ¹ýÀû, À±¸®Àû À̽´ ±è¸¸Áø(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06¿ù 14ÀÏ ¼¼¼ÇA(¿¤¸®¿¡³ªÈ£ÅÚ 3F ÀÓÆ丮¾óȦ) 10:00~10:30 À¯ÀüÀÚ °Ë»ç ½Ç¹« – °Ë»ç´ë»ó¹°/À¯ÀüÁ¤º¸/°³ÀÎÁ¤º¸ °ü¸® ¼ÕÁö¿¬(ÀÌ¿øÀÇ·áÀç´Ü)
±³À°½Ã°£ 06¿ù 14ÀÏ ¼¼¼ÇA(¿¤¸®¿¡³ªÈ£ÅÚ 3F ÀÓÆ丮¾óȦ) 12:30~13:00 HPV°Ë»ç ÀÓ»ó±Ç°í¾È ¼ö¸³ °èȹ ¹× ÇöȲ À̽ÅÈ(¼¿ï¾Æ»êº´¿ø »êºÎÀΰú)
±³À°½Ã°£ 06¿ù 14ÀÏ ¼¼¼ÇA(¿¤¸®¿¡³ªÈ£ÅÚ 3F ÀÓÆ丮¾óȦ) 13:00~13:30 Highly Sensitive Detection of Early Stage HCC using PCR based Liquid Biopsy ±è¿µÁØ(¿¬¼¼´ë)
±³À°½Ã°£ 06¿ù 14ÀÏ ¼¼¼ÇA(¿¤¸®¿¡³ªÈ£ÅÚ 3F ÀÓÆ丮¾óȦ) 13:30~14:00 Clinical Application of Urine as a Source of Liquid Biopsy for Urological Cancer ¿øµ¿ÁÖ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 06¿ù 14ÀÏ ¼¼¼ÇA(¿¤¸®¿¡³ªÈ£ÅÚ 3F ÀÓÆ丮¾óȦ) 14:00~14:30 Fusion Detection using Circulating Tumor DNA Assays : The Value and Challenges ±è¿µ°ï(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 06¿ù 14ÀÏ ¼¼¼ÇA(¿¤¸®¿¡³ªÈ£ÅÚ 3F ÀÓÆ丮¾óȦ) 15:00~15:30 Sanger RNA Sequencing without NMD Inhibition and Variant Reclassification ÇÏâÈñ(°Ç±¹ÀÇ´ë)
±³À°½Ã°£ 06¿ù 14ÀÏ ¼¼¼ÇA(¿¤¸®¿¡³ªÈ£ÅÚ 3F ÀÓÆ丮¾óȦ) 15:30~16:00 RNA Sequencing Analysis Pipeline for Clinical Application ¹ÚÁ¾È£(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 06¿ù 14ÀÏ ¼¼¼ÇA(¿¤¸®¿¡³ªÈ£ÅÚ 3F ÀÓÆ丮¾óȦ) 16:00~16:30 Introducing Single-Cell RNA Sequencing and Its Applicability Àå¹Ì¾Ö(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 06¿ù 14ÀÏ ¼¼¼ÇB(¿¤¸®¿¡³ªÈ£ÅÚ 2F ÄÁº¥¼ÇȦ) 10:45~11:10 Longitudinal Detection of ctDNA in Non-Hodgkin Lymphoma ¼ºÁö¿¬(Çѱ¹·Î½´Áø´Ü)
±³À°½Ã°£ 06¿ù 14ÀÏ ¼¼¼ÇB(¿¤¸®¿¡³ªÈ£ÅÚ 2F ÄÁº¥¼ÇȦ) 10:45~11:10 Single-Cell and Single-Microbe High-Throughput Sequencing Solution Yanquan Luo(MobiDrop)
±³À°½Ã°£ 06¿ù 14ÀÏ ¼¼¼ÇB(¿¤¸®¿¡³ªÈ£ÅÚ 2F ÄÁº¥¼ÇȦ) 11:10~11:35 Evaluation of a New Sequencing Instrument, AVITI À̽ÂÅÂ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 06¿ù 14ÀÏ ¼¼¼ÇB(¿¤¸®¿¡³ªÈ£ÅÚ 2F ÄÁº¥¼ÇȦ) 11:10~11:35 Genetic Diagnosis Utilizing xGen Exome and mtDNA Research Solution ¼³Ã¢¾È(GCÁö³ð)
±³À°½Ã°£ 06¿ù 14ÀÏ ¼¼¼ÇB(¿¤¸®¿¡³ªÈ£ÅÚ 2F ÄÁº¥¼ÇȦ) 11:35~12:00 Using Genomic Tools for Genetic Disease Investigation and Cytogenetic Screening Thomas Kleem(´Ù¿ì¹ÙÀÌ¿À¸ÞµðÄ«&ÀÏ·ç¹Ì³ª)
±³À°½Ã°£ 06¿ù 14ÀÏ ¼¼¼ÇB(¿¤¸®¿¡³ªÈ£ÅÚ 2F ÄÁº¥¼ÇȦ) 11:35~12:00 Application of Biomarker Testing for Precision Medicine Approach ÀÌ°æ¾Æ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 06¿ù 14ÀÏ ¼¼¼ÇB(¿¤¸®¿¡³ªÈ£ÅÚ 2F ÄÁº¥¼ÇȦ) 13:00~13:30 NGS MRD for Hematologic Malignancies ±èÁøÁÖ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 06¿ù 14ÀÏ ¼¼¼ÇB(¿¤¸®¿¡³ªÈ£ÅÚ 2F ÄÁº¥¼ÇȦ) 13:30~14:00 Digital Droplet PCR in Hematologic Malignancies ±èÇöÁö(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06¿ù 14ÀÏ ¼¼¼ÇB(¿¤¸®¿¡³ªÈ£ÅÚ 2F ÄÁº¥¼ÇȦ) 14:00~14:30 Liquid Biopsy for Lymphoma ±èÈ«°æ(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 06¿ù 14ÀÏ ¼¼¼ÇB(¿¤¸®¿¡³ªÈ£ÅÚ 2F ÄÁº¥¼ÇȦ) 15:00~15:30 Ç÷¾×¾Ï À¯ÀüÀڰ˻翡¼ ¹ß°ßµÇ´Â somatic variant Çؼ® ¹× º¸°í Áöħ/±Ç°í¾È ±èÇö¿µ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 06¿ù 14ÀÏ ¼¼¼ÇB(¿¤¸®¿¡³ªÈ£ÅÚ 2F ÄÁº¥¼ÇȦ) 15:30~16:00 Ç÷¾×¾Ï ȯÀÚ¿¡¼ MRD monitoring °Ë»ç °á°ú Çؼ® ¹× º¸°í Áöħ/±Ç°í¾È ±è¹Ì¿µ(¿ï»êÀÇ´ë)